UAE Business Setup
Free zone, mainland, DIFC, or ADGM, with Corporate Tax and banking analysis.
Market Access & Regulatory
The UAE rewards preparation and punishes assumption. Entry decisions set the ceiling for years.
Entity structure, jurisdiction, and licensing decided at establishment set tax exposure, banking access, market reach, and ownership rights for years, and they are costly to unwind. We manage market entry and regulatory execution where the stakes are too high for a formation agent who files an application without telling you what it costs you.
Who engages this
International healthcare operators entering under DHA or DOH, pharma and device companies seeking Emirates Drug Establishment (EDE) or DHA approval, businesses expanding market by market across the GCC, and family offices structuring UAE holdings engage this pillar. Healthcare licensing runs in sequence: a misstep at stage two does not surface until stage six.
The work
What this practice takes on.
Healthcare UAE Entry
DHA and DOH licensing, feasibility, and commissioning, managed end to end.
Pharma Registration
EDE authorisation, medical device registration, and pharmacovigilance design.
Pharma Manufacturing Setup
Nine-stage programme from feasibility to WHO/EU GMP certification.
GCC Expansion
Country-by-country entry across six markets, with distributor due diligence.
Corporate Migration & Wealth
DIFC and ADGM family offices and UAE holding structures for HNWIs.
On a mandate
An international hospital group signed a Dubai property lease on a real estate advisor's assessment, then found the layout failed DHA minimum standards for its intended clinical scope. We ran a scope redesign, requested a DHA pre-application meeting, and phased the licensing, separating two clinics from the day surgery centre so the compliant streams proceeded while the surgery stream was remediated. Both clinics licensed on the original timeline; the surgery licence followed six months later. A pre-application meeting takes four to six weeks and would have caught it before the lease.
Questions
What clients ask first.
Which regulator licenses my healthcare facility?
DHA governs healthcare in Dubai, DOH in Abu Dhabi, and MOHAP the Northern Emirates, each with its own licensing framework, inspectable standards, and change-of-control provisions. Federal drug and medical-device registration now sits with the Emirates Drug Establishment (EDE), which took over from MOHAP at the end of 2025. The emirate you operate in determines which facility regulator applies.
How long does EDE product registration take?
A well-prepared CTD dossier takes twelve to eighteen months from submission to marketing authorisation. A dossier that triggers a major query cycle adds six to twelve months, usually because the pre-submission meeting was skipped. Where a product already holds approval from a stringent reference agency, EDE's verification pathway is materially faster. That early engagement is our highest-value intervention.
Free zone or mainland for a UAE business?
It depends on your commercial model. A free zone entity cannot trade directly with the mainland market without a distributor or second licence, and qualifying income for zero Corporate Tax has a precise definition. If you sell into the domestic market or run a licensed facility, mainland is usually required.
Can a foreign company own 100% of a UAE healthcare business?
Yes. Since Federal Decree-Law No. 32 of 2021 on Commercial Companies, healthcare is not among the restricted Activities of Strategic Effect, so a foreign investor can hold full ownership of a mainland healthcare company, subject to the activity appearing on the emirate's positive list. Ownership is not the constraint that decides your timeline, though. The facility still needs a separate licence from the emirate's health regulator, DHA in Dubai, DOH in Abu Dhabi, MOHAP in the Northern Emirates, which assesses clinical scope, physical standards, and staffing on its own schedule. And a free-zone entity, while fully foreign-owned, cannot sell directly into the domestic market without a distributor or a second licence. The ownership question is usually settled quickly; the licensing sequence is where entrants lose time.
Entry decisions are hard to reverse. Speak with a principal before the structure is set.